No Data
No Data
12 Health Care Stocks Moving In Thursday's After-Market Session
Buy Rating on Lipella Pharmaceuticals Backed by Promising Phase 2a Results for Oral Lichen Planus Treatment
PRISM MarketView Features Q&A With Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month
Lipella Pharmaceuticals Announces Update On Phase 2a Trial Of LP-310 In Oral Lichen Planus; Three Participants Completed The Four-week Treatment, Says Treatment Was Well Tolerated And Had No Unpleasant Taste
Express News | Lipella Pharmaceuticals Inc - Trial to Conclude by Mid-2025, Top-Line Data by Year-End 2024
Express News | Lipella Pharmaceuticals Inc - LP-310 Treatment Well Tolerated With No Unpleasant Taste
No Data
No Data